Mubarak Al-Kabeer Hospital (Arabic: مستشفى مبارك الكبير) is a general hospital built in Jabriya, Kuwait in 1982. The hospital was named after Shiekh Mubarak Al-Kabeer Al-Sabah. It serves the Hawalli Governorate and covers about 700,000 people in the area. It consists of all departments. All the nationalities living in Kuwait can go in this hospital. All patients who come in the hospital should bring their CIVIL ID CARD.
Aim of the work Large registry studies have characterized the clinical features and treatment patterns of axial spondyloarthritis (axSpA); however, multicenter data from Arab populations remain scarce. We describe the baseline characteristics and treatment patterns of patients enrolled in the Kuwait axSpA Registry and place them in the context of international cohorts.
Obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), and chronic kidney disease (CKD) are overlapping conditions that drive premature morbidity and mortality worldwide. Care remains siloed and reactive despite shared risk factors and strong evidence for early intervention. To support integrated disease management, the American Heart Association (AHA) recently introduced the concept of cardiovascular–kidney–metabolic (CKM) syndrome, recognizing the bidirectional links between metabolic, kidney, and cardiovascular health. Kuwait faces one of the highest burdens of CKM-related diseases globally. Three-quarters of adults are overweight or have obesity, and 28
The growth of musculoskeletal ultrasound (US) has led to an increasing trend of US-guided interventions also/sometimes being performed by allied health professionals who lack formal comprehensive medical training. This international expert opinion - developed through structured consultation among 20 Physical and Rehabilitation Medicine (PRM) physicians from 14 countries across five continents - addresses the patient safety, ethical, and medicolegal concerns arising from non-physicians performing such interventions. A narrative literature synthesis was conducted and iteratively reviewed by all contributing authors whereas formal consensus methodology was not employed. Having reviewed the international regulatory landscape, including regulations from the United States, Europe (Germany, France, Italy, Spain, Scandinavian countries, and the United Kingdom), and the Asia-Pacific region; we highlight inconsistencies that may compromise patient welfare. We call upon PRM associations to develop unified position statements establishing minimum competency standards. Policy recommendations would include establishing international complication registries, implementing enforceable supervision protocols, strengthening informed consent requirements, and ensuring transparent provider identification. Through these measures, professional organizations, regulators, and healthcare institutions can promote patient safety, transparency, and consistent standards worldwide.
Abstract: BACKGROUND: Rheumatoid arthritis (RA), a chronic autoimmune disease, is increasingly prevalent in the Middle East. Although treatment guidelines are informed by randomized controlled trials, real-world evidence on the long-term effectiveness and safety of Janus kinase inhibitors such as upadacitinib (UPA) in Gulf Cooperation Council (GCC) countries remains limited. OBJECTIVE: To evaluate the effectiveness and safety of long-term UPA 15 mg once daily in patients from GCC countries with moderate-to-severe RA, focusing on treatment targets and response maintenance in real-world settings. METHODOLOGY: This is a subgroup analysis of the UPHOLD trial (NCT04497597), a prospective, multicenter, noninterventional study. UPA-naïve adults with moderate-to-severe RA received UPA 15 mg once daily as monotherapy or combined with other disease-modifying antirheumatic drugs. Co-primary endpoints were DAS28-CRP remission (<2.6) at 6 months and its maintenance at 12 months. Safety was also assessed. RESULTS: Of 94 patients enrolled, 43.9% achieved DAS28-CRP remission at 6 months, and 81.8% maintained remission at 12 months. In addition, 52.6% achieved low disease activity (LDA) at 6 months, with 81.8% maintaining it at 12 months. Patient-reported outcomes (Patient’s Global Assessment and Health Assessment Questionnaire Disability Index scores) improved significantly. Treatment-emergent adverse events (TEAEs) were reported in 45.7%, most of which were mild (33%) or moderate (27.7%) in severity. Severe and serious TEAEs occurred in 6.4% and 8.5%, respectively. No new safety signals were identified. CONCLUSION: UPA 15 mg once daily demonstrated effectiveness in achieving and maintaining remission and LDA in patients with moderate-to-severe RA in real-world clinical practice from GCC countries, with a manageable safety profile.
